;PMID: 12120897
;source_file_1939.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..185] = [t:49..185]
;2)section:[e:189..235] = [t:189..235]
;3)section:[e:239..336] = [t:239..336]
;4)sentence:[e:340..527] = [t:340..527]
;5)sentence:[e:528..627] = [t:528..627]
;6)sentence:[e:628..673] = [t:628..673]
;7)sentence:[e:674..817] = [t:674..817]
;8)sentence:[e:818..921] = [t:818..921]
;9)sentence:[e:922..1077] = [t:922..1077]
;10)sentence:[e:1078..1177] = [t:1078..1177]
;11)sentence:[e:1178..1494] = [t:1178..1494]
;12)sentence:[e:1495..1638] = [t:1495..1638]
;13)sentence:[e:1639..1835] = [t:1639..1835]
;14)sentence:[e:1836..2109] = [t:1836..2109]
;15)sentence:[e:2110..2250] = [t:2110..2250]
;16)sentence:[e:2251..2474] = [t:2251..2474]
;17)sentence:[e:2475..2545] = [t:2475..2545]
;18)sentence:[e:2546..2721] = [t:2546..2721]
;19)sentence:[e:2722..2837] = [t:2722..2837]
;20)sentence:[e:2838..3008] = [t:2838..3008]
;21)section:[e:3012..3057] = [t:3012..3057]

;section 0 Span:0..43
;J Physiol Pharmacol. 2002 Jun;53(2):211-31.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Physiol) (NNP:[10..19] Pharmacol)
        (.:[19..20] .) (CD:[21..25] 2002) (CC:[26..33] Jun;53-LRB-)
        (CD:[33..34] 2) (-RRB-:[34..35] -RRB-) (::[35..36] :)
        (CD:[36..42] 211-31) (.:[42..43] .)))

;sentence 1 Span:49..185
;The opposite effects of cyclic AMP-protein kinase a signal transduction
;pathway  on renal cortical and medullary Na+,K+-ATPase activity.
;[73..83]:substance:"cyclic AMP"
;[84..98]:substance:"protein kinase"
;[162..165]...[168..175]:substance:"Na+"..."-ATPase"
;[166..175]:substance:"K+-ATPase"
(SENT
  (NP-HLN
    (NP (DT:[49..52] The) (JJ:[53..61] opposite) (NNS:[62..69] effects))
    (PP (IN:[70..72] of)
      (NP
        (NP
          (NP
            (NML (JJ:[73..79] cyclic) (NN:[80..83] AMP))
            (HYPH:[83..84] -) (NN:[84..91] protein))
          (NN:[92..98] kinase))
        (NP (NN:[99..100] a) (NN:[101..107] signal) (NN:[108..120] transduction)
            (NN:[121..128] pathway))))
    (PP (IN:[130..132] on)
      (NP
        (NP
          (ADJP
            (ADJP-1 (JJ:[133..138] renal))
            (JJ:[139..147] cortical))
          (NML-2 (-NONE-:[147..147] *P*))
          (NML-3 (-NONE-:[147..147] *P*)))
        (CC:[148..151] and)
        (NP
          (ADJP
            (ADJP-1 (-NONE-:[151..151] *P*))
            (JJ:[152..161] medullary))
          (NML-2
            (NML
              (NML (NN:[162..164] Na) (SYM:[164..165] +))
              (,:[165..166] ,)
              (NML (NN:[166..167] K) (SYM:[167..168] +)))
            (HYPH:[168..169] -) (NN:[169..175] ATPase))
          (NML-3 (NN:[176..184] activity)))))
    (.:[184..185] .)))

;section 2 Span:189..235
;Beltowski J, Marciniak A, Wojcicka G, Gorny D.
(SEC
  (FRAG (NNP:[189..198] Beltowski) (NNP:[199..201] J,)
        (NNP:[202..211] Marciniak) (NNP:[212..213] A) (,:[213..214] ,)
        (NNP:[215..223] Wojcicka) (NNP:[224..225] G) (,:[225..226] ,)
        (NNP:[227..232] Gorny) (NNP:[233..235] D.)))

;section 3 Span:239..336
;Department of Pathophysiology, Medical University, Lublin, Poland. 
;patfiz@asklepios.am.lublin.pl
(SEC
  (FRAG (NNP:[239..249] Department) (IN:[250..252] of)
        (NNP:[253..268] Pathophysiology) (,:[268..269] ,)
        (NNP:[270..277] Medical) (NNP:[278..288] University) (,:[288..289] ,)
        (NNP:[290..296] Lublin) (,:[296..297] ,) (NNP:[298..304] Poland)
        (.:[304..305] .) (NNS:[307..323] patfiz@asklepios) (VBD:[323..326] .am)
        (NN:[326..333] .lublin) (.:[333..336] .pl)))

;sentence 4 Span:340..527
;Cyclic AMP-protein kinase A (PKA) pathway plays an important role in signal 
;transduction in renal tubular cells, however, its role in transport
;regulation  is not completely established.
;[340..350]:substance:"Cyclic AMP"
;[351..367]:substance:"protein kinase A"
;[369..372]:substance:"PKA"
(SENT
  (S
    (S
      (NP-SBJ
        (NML
          (NML (JJ:[340..346] Cyclic) (NN:[347..350] AMP))
          (HYPH:[350..351] -)
          (NML
            (NML (NN:[351..358] protein) (NN:[359..365] kinase)
                 (NN:[366..367] A))
            (NP (-LRB-:[368..369] -LRB-) (NN:[369..372] PKA)
                (-RRB-:[372..373] -RRB-))))
        (NN:[374..381] pathway))
      (VP (VBZ:[382..387] plays)
        (NP
          (NP (DT:[388..390] an) (JJ:[391..400] important) (NN:[401..405] role))
          (PP (IN:[406..408] in)
            (NP (NN:[409..415] signal) (NN:[417..429] transduction))))
        (PP-LOC (IN:[430..432] in)
          (NP
            (ADJP (JJ:[433..438] renal) (JJ:[439..446] tubular))
            (NNS:[447..452] cells)))
        (,:[452..453] ,)
        (S-ADV
          (ADVP (RB:[454..461] however))
          (,:[461..462] ,)
          (NP-SBJ-1
            (NP (PRP$:[463..466] its) (NN:[467..471] role))
            (PP (IN:[472..474] in)
              (NP (NN:[475..484] transport) (NN:[485..495] regulation))))
          (VP (VBZ:[497..499] is) (RB:[500..503] not)
            (VP
              (ADVP (RB:[504..514] completely))
              (VBN:[515..526] established)
              (NP-1 (-NONE-:[526..526] *)))))))
    (.:[526..527] .)))

;sentence 5 Span:528..627
;The aim of this study was to investigate in vivo  the effect of PKA on renal
;Na, K-ATPase activity.
;[592..595]:substance:"PKA"
;[605..607]...[610..617]:substance:"Na"..."-ATPase"
;[609..617]:substance:"K-ATPase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[528..531] The) (NN:[532..535] aim))
      (PP (IN:[536..538] of)
        (NP (DT:[539..543] this) (NN:[544..549] study))))
    (VP (VBD:[550..553] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[553..553] *))
        (VP (TO:[554..556] to)
          (VP (VB:[557..568] investigate)
            (ADVP (FW:[569..571] in) (FW:[572..576] vivo))
            (NP
              (NP (DT:[578..581] the) (NN:[582..588] effect))
              (PP (IN:[589..591] of)
                (NP (NN:[592..595] PKA)))
              (PP (IN:[596..598] on)
                (NP (JJ:[599..604] renal)
                  (NML
                    (NML (NN:[605..607] Na) (,:[607..608] ,) (NN:[609..610] K))
                    (HYPH:[610..611] -) (NN:[611..617] ATPase))
                  (NN:[618..626] activity))))))))
    (.:[626..627] .)))

;sentence 6 Span:628..673
;The study was performed in  male Wistar rats.
(SENT
  (S
    (NP-SBJ-1 (DT:[628..631] The) (NN:[632..637] study))
    (VP (VBD:[638..641] was)
      (VP (VBN:[642..651] performed)
        (NP-1 (-NONE-:[651..651] *))
        (PP-LOC (IN:[652..654] in)
          (NP (JJ:[656..660] male) (NNP:[661..667] Wistar) (NNS:[668..672] rats)))))
    (.:[672..673] .)))

;sentence 7 Span:674..817
;The animals were anaesthetized with pentobarbital and  investigated drugs
;were infused through the catheter inserted into the abdominal  aorta.
;[710..723]:substance:"pentobarbital"
;[742..747]:substance:"drugs"
(SENT
  (S
    (S
      (NP-SBJ-2 (DT:[674..677] The) (NNS:[678..685] animals))
      (VP (VBD:[686..690] were)
        (VP (VBN:[691..704] anaesthetized)
          (NP-2 (-NONE-:[704..704] *))
          (PP-MNR (IN:[705..709] with)
            (NP (NN:[710..723] pentobarbital))))))
    (CC:[724..727] and)
    (S
      (NP-SBJ-1 (VBN:[729..741] investigated) (NNS:[742..747] drugs))
      (VP (VBD:[748..752] were)
        (VP (VBN:[753..760] infused)
          (NP-1 (-NONE-:[760..760] *))
          (PP-MNR (IN:[761..768] through)
            (NP
              (NP (DT:[769..772] the) (NN:[773..781] catheter))
              (VP (VBN:[782..790] inserted)
                (NP (-NONE-:[790..790] *))
                (PP (IN:[791..795] into)
                  (NP (DT:[796..799] the) (JJ:[800..809] abdominal)
                      (NN:[811..816] aorta)))))))))
    (.:[816..817] .)))

;sentence 8 Span:818..921
;Na+,K+-ATPase activity was assayed in an isolated microsomal fraction of  the
;renal cortex and medulla.
;[818..821]...[824..831]:substance:"Na+"..."-ATPase"
;[822..831]:substance:"K+-ATPase"
(SENT
  (S
    (NP-SBJ-2
      (NML
        (NML
          (NML (NN:[818..820] Na) (SYM:[820..821] +))
          (,:[821..822] ,)
          (NML (NN:[822..823] K) (SYM:[823..824] +)))
        (HYPH:[824..825] -) (NN:[825..831] ATPase))
      (NN:[832..840] activity))
    (VP (VBD:[841..844] was)
      (VP (VBN:[845..852] assayed)
        (NP-2 (-NONE-:[852..852] *))
        (PP-LOC (IN:[853..855] in)
          (NP
            (NP (DT:[856..858] an) (VBN:[859..867] isolated)
                (JJ:[868..878] microsomal) (NN:[879..887] fraction))
            (PP (IN:[888..890] of)
              (NP (DT:[892..895] the)
                (NML
                  (NML
                    (ADJP-1 (JJ:[896..901] renal))
                    (NN:[902..908] cortex))
                  (CC:[909..912] and)
                  (NML
                    (ADJP-1 (-NONE-:[912..912] *P*))
                    (NN:[913..920] medulla)))))))))
    (.:[920..921] .)))

;sentence 9 Span:922..1077
;Cell-permeable cAMP analogue, dibutyryl-cAMP  (db-cAMP), dose-dependently
;stimulated Na+,K+-ATPase in the renal cortex and  inhibited in the renal
;medulla.
;[937..950]:substance:"cAMP analogue"
;[952..966]:substance:"dibutyryl-cAMP"
;[969..976]:substance:"db-cAMP"
;[1007..1010]...[1013..1020]:substance:"Na+"..."-ATPase"
;[1011..1020]:substance:"K+-ATPase"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP (NN:[922..926] Cell) (HYPH:[926..927] -) (JJ:[927..936] permeable))
         (NN:[937..941] cAMP) (NN:[942..950] analogue))
      (,:[950..951] ,)
      (NP
        (NP (NN:[952..966] dibutyryl-cAMP))
        (NP (-LRB-:[968..969] -LRB-) (NN:[969..976] db-cAMP)
            (-RRB-:[976..977] -RRB-))))
    (,:[977..978] ,)
    (ADVP (NN:[979..983] dose) (HYPH:[983..984] -) (RB:[984..995] dependently))
    (VP
      (VP (VBD:[996..1006] stimulated)
        (NP
          (NML
            (NML (NN:[1007..1009] Na) (SYM:[1009..1010] +))
            (,:[1010..1011] ,)
            (NML (NN:[1011..1012] K) (SYM:[1012..1013] +)))
          (HYPH:[1013..1014] -) (NN:[1014..1020] ATPase))
        (PP-LOC (IN:[1021..1023] in)
          (NP (DT:[1024..1027] the) (JJ:[1028..1033] renal)
              (NN:[1034..1040] cortex))))
      (CC:[1041..1044] and)
      (VP (VBD:[1046..1055] inhibited)
        (PP-LOC (IN:[1056..1058] in)
          (NP (DT:[1059..1062] the) (JJ:[1063..1068] renal)
              (NN:[1069..1076] medulla)))))
    (.:[1076..1077] .)))

;sentence 10 Span:1078..1177
;Maximal stimulation (+38.5%) and inhibition  (-46.8%) were observed at a dose
;of 10(-6) mol/kg/min.
;[1099..1105]:quantitative-value:"+38.5%"
;[1124..1130]:quantitative-value:"-46.8%"
;[1159..1165]:quantitative-value:"10(-6)"
;[1166..1176]:quantitative-units:"mol/kg/min"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (ADJP-1 (JJ:[1078..1085] Maximal))
        (NN:[1086..1097] stimulation)
        (PRN (-LRB-:[1098..1099] -LRB-)
          (NP (SYM:[1099..1100] +) (CD:[1100..1104] 38.5) (NN:[1104..1105] %))
          (-RRB-:[1105..1106] -RRB-)))
      (CC:[1107..1110] and)
      (NP
        (ADJP-1 (-NONE-:[1110..1110] *P*))
        (NN:[1111..1121] inhibition)
        (PRN (-LRB-:[1123..1124] -LRB-)
          (NP (SYM:[1124..1125] -) (CD:[1125..1129] 46.8) (NN:[1129..1130] %))
          (-RRB-:[1130..1131] -RRB-))))
    (VP (VBD:[1132..1136] were)
      (VP (VBN:[1137..1145] observed)
        (NP-2 (-NONE-:[1145..1145] *))
        (PP (IN:[1146..1148] at)
          (NP
            (NP (DT:[1149..1150] a) (NN:[1151..1155] dose))
            (PP (IN:[1156..1158] of)
              (NP
                (NP (CD:[1159..1165] 10-LRB--6-RRB-) (NN:[1166..1169] mol))
                (PP (SYM:[1169..1170] /)
                  (NP (NN:[1170..1172] kg)))
                (PP (SYM:[1172..1173] /)
                  (NP (NN:[1173..1176] min)))))))))
    (.:[1176..1177] .)))

;sentence 11 Span:1178..1494
;Measurement of  Na+,K+-ATPase activity at different Na' concentrations
;revealed that in the  renal cortex db-cAMP increased Vmax of the enzyme
;without any effect on sodium  affinity, whereas in the renal medulla decrease
;in Vmax was accompanied by  decreased sodium affinity, evidenced by elevated
;K(0.5) for sodium.
;[1194..1197]...[1200..1207]:substance:"Na+"..."-ATPase"
;[1198..1207]:substance:"K+-ATPase"
;[1230..1232]:substance:"Na"
;[1284..1291]:substance:"db-cAMP"
;[1302..1306]:quantitative-name:"Vmax"
;[1314..1320]:substance:"enzyme"
;[1343..1349]:substance:"sodium"
;[1402..1406]:quantitative-name:"Vmax"
;[1437..1443]:substance:"sodium"
;[1476..1482]:quantitative-name:"K(0.5)"
;[1487..1493]:substance:"sodium"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1178..1189] Measurement))
      (PP (IN:[1190..1192] of)
        (NP
          (NML
            (NML
              (NML (NN:[1194..1196] Na) (SYM:[1196..1197] +))
              (,:[1197..1198] ,)
              (NML (NN:[1198..1199] K) (SYM:[1199..1200] +)))
            (HYPH:[1200..1201] -) (NN:[1201..1207] ATPase))
          (NN:[1208..1216] activity)))
      (PP (IN:[1217..1219] at)
        (NP (JJ:[1220..1229] different)
          (NML (NN:[1230..1232] Na) (SYM:[1232..1233] '))
          (NNS:[1234..1248] concentrations))))
    (VP (VBD:[1249..1257] revealed)
      (SBAR (IN:[1258..1262] that)
        (S
          (PP-LOC (IN:[1263..1265] in)
            (NP (DT:[1266..1269] the) (JJ:[1271..1276] renal)
                (NN:[1277..1283] cortex)))
          (NP-SBJ (NN:[1284..1291] db-cAMP))
          (VP (VBD:[1292..1301] increased)
            (NP
              (NP (NN:[1302..1306] Vmax))
              (PP (IN:[1307..1309] of)
                (NP (DT:[1310..1313] the) (NN:[1314..1320] enzyme))))
            (PP (IN:[1321..1328] without)
              (NP
                (NP (DT:[1329..1332] any) (NN:[1333..1339] effect))
                (PP (IN:[1340..1342] on)
                  (NP (NN:[1343..1349] sodium) (NN:[1351..1359] affinity)))))
            (,:[1359..1360] ,)
            (SBAR-ADV (IN:[1361..1368] whereas)
              (S
                (PP-LOC (IN:[1369..1371] in)
                  (NP (DT:[1372..1375] the) (JJ:[1376..1381] renal)
                      (NN:[1382..1389] medulla)))
                (NP-SBJ-1
                  (NP (NN:[1390..1398] decrease))
                  (PP (IN:[1399..1401] in)
                    (NP (NN:[1402..1406] Vmax))))
                (VP (VBD:[1407..1410] was)
                  (VP (VBN:[1411..1422] accompanied)
                    (NP-1 (-NONE-:[1422..1422] *))
                    (PP (IN:[1423..1425] by)
                      (NP-LGS
                        (NP (VBN:[1427..1436] decreased)
                            (NN:[1437..1443] sodium) (NN:[1444..1452] affinity))
                        (,:[1452..1453] ,)
                        (VP (VBN:[1454..1463] evidenced)
                          (NP (-NONE-:[1463..1463] *))
                          (PP (IN:[1464..1466] by)
                            (NP
                              (NP (VBN:[1467..1475] elevated)
                                 (NN:[1476..1477] K)
                                (PRN (-LRB-:[1477..1478] -LRB-)
                                  (NP (CD:[1478..1481] 0.5))
                                  (-RRB-:[1481..1482] -RRB-)))
                              (PP (IN:[1483..1486] for)
                                (NP (NN:[1487..1493] sodium))))))))))))))))
    (.:[1493..1494] .)))

;sentence 12 Span:1495..1638
;The effect  of db-cAMP was mimicked by the infusion of either adenylate
;cyclase activator,  forskolin, or inhibitor of phosphodiesterase, IBMX.
;[1510..1517]:substance:"db-cAMP"
;[1557..1574]:substance:"adenylate cyclase"
;[1575..1584]:substance:"activator"
;[1587..1596]:substance:"forskolin"
;[1601..1610]:substance:"inhibitor"
;[1614..1631]:substance:"phosphodiesterase"
;[1633..1637]:substance:"IBMX"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1495..1498] The) (NN:[1499..1505] effect))
      (PP (IN:[1507..1509] of)
        (NP (NN:[1510..1517] db-cAMP))))
    (VP (VBD:[1518..1521] was)
      (VP (VBN:[1522..1530] mimicked)
        (NP-1 (-NONE-:[1530..1530] *))
        (PP (IN:[1531..1533] by)
          (NP
            (NP (DT:[1534..1537] the) (NN:[1538..1546] infusion))
            (PP (IN:[1547..1549] of)
              (NP (CC:[1550..1556] either)
                (NP
                  (NP
                    (NML (NN:[1557..1566] adenylate) (NN:[1567..1574] cyclase))
                    (NN:[1575..1584] activator))
                  (,:[1584..1585] ,)
                  (NP (NN:[1587..1596] forskolin)))
                (,:[1596..1597] ,) (CC:[1598..1600] or)
                (NP
                  (NP
                    (NP (NN:[1601..1610] inhibitor))
                    (PP (IN:[1611..1613] of)
                      (NP (NN:[1614..1631] phosphodiesterase))))
                  (,:[1631..1632] ,)
                  (NP (NN:[1633..1637] IBMX)))))))))
    (.:[1637..1638] .)))

;sentence 13 Span:1639..1835
;Both stimulatory and  inhibitory effects of db-cAMP were prevented by
;pretreatment with protein kinase  A inhibitor, KT 5720 (10(-8) mol/kg/min)
;but not by inhibitor of protein kinase  G, KT 5823.
;[1683..1690]:substance:"db-cAMP"
;[1727..1744]:substance:"protein kinase  A"
;[1745..1754]:substance:"inhibitor"
;[1756..1763]:substance:"KT 5720"
;[1765..1771]:quantitative-value:"10(-8)"
;[1772..1782]:quantitative-units:"mol/kg/min"
;[1795..1804]:substance:"inhibitor"
;[1808..1825]:substance:"protein kinase  G"
;[1827..1834]:substance:"KT 5823"
(SENT
  (S
    (NP-SBJ-4
      (NP (CC:[1639..1643] Both)
        (NP (JJ:[1644..1655] stimulatory)
          (NML-3 (-NONE-:[1655..1655] *P*)))
        (CC:[1656..1659] and)
        (NP (JJ:[1661..1671] inhibitory)
          (NML-3 (NNS:[1672..1679] effects))))
      (PP (IN:[1680..1682] of)
        (NP (NN:[1683..1690] db-cAMP))))
    (VP (VBD:[1691..1695] were)
      (VP
        (VP (VBN:[1696..1705] prevented)
          (NP-4 (-NONE-:[1705..1705] *))
          (PP=2 (IN:[1706..1708] by)
            (NP-LGS
              (NP (NN:[1709..1721] pretreatment))
              (PP (IN:[1722..1726] with)
                (NP
                  (NP
                    (NML
                      (NML (NN:[1727..1734] protein) (NN:[1735..1741] kinase))
                      (NN:[1743..1744] A))
                    (NN:[1745..1754] inhibitor))
                  (,:[1754..1755] ,)
                  (NP (NN:[1756..1758] KT) (CD:[1759..1763] 5720))))))
          (PRN (-LRB-:[1764..1765] -LRB-)
            (NP
              (NP (CD:[1765..1771] 10-LRB--8-RRB-) (NN:[1772..1775] mol))
              (PP (SYM:[1775..1776] /)
                (NP (NN:[1776..1778] kg)))
              (PP (SYM:[1778..1779] /)
                (NP (NN:[1779..1782] min))))
            (-RRB-:[1782..1783] -RRB-)))
        (CC:[1784..1787] but)
        (VP (RB:[1788..1791] not)
          (NP-4 (-NONE-:[1791..1791] *))
          (PP=2 (IN:[1792..1794] by)
            (NP-LGS
              (NP
                (NP (NN:[1795..1804] inhibitor))
                (PP (IN:[1805..1807] of)
                  (NP
                    (NML (NN:[1808..1815] protein) (NN:[1816..1822] kinase))
                    (NN:[1824..1825] G))))
              (,:[1825..1826] ,)
              (NP (NN:[1827..1829] KT) (CD:[1830..1834] 5823)))))))
    (.:[1834..1835] .)))

;sentence 14 Span:1836..2109
;The inhibitory effect in the renal medulla was partially blocked by 
;pretreatment with either ethoxyresorufin or 17-ODYA - two nonspecific
;inhibitors  of cytochrome P450-dependent arachidonate metabolism, whereas an
;inhibitor of  epoxygenase, miconazole, was not effective.
;[1930..1945]:substance:"ethoxyresorufin"
;[1949..1956]:substance:"17-ODYA"
;[1975..1985]:substance:"inhibitors"
;[1990..2005]:cyp450:"cytochrome P450"
;[2016..2028]:substance:"arachidonate"
;[2052..2061]:substance:"inhibitor"
;[2066..2077]:substance:"epoxygenase"
;[2079..2089]:substance:"miconazole"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (DT:[1836..1839] The) (JJ:[1840..1850] inhibitory)
            (NN:[1851..1857] effect))
        (PP-LOC (IN:[1858..1860] in)
          (NP (DT:[1861..1864] the) (JJ:[1865..1870] renal)
              (NN:[1871..1878] medulla))))
      (VP (VBD:[1879..1882] was)
        (ADVP (RB:[1883..1892] partially))
        (VP (VBN:[1893..1900] blocked)
          (NP-1 (-NONE-:[1900..1900] *))
          (PP (IN:[1901..1903] by)
            (NP-LGS
              (NP (NN:[1905..1917] pretreatment))
              (PP (IN:[1918..1922] with)
                (NP
                  (NP (CC:[1923..1929] either) (NN:[1930..1945] ethoxyresorufin)
                      (CC:[1946..1948] or) (NN:[1949..1956] 17-ODYA))
                  (::[1957..1958] -)
                  (NP
                    (NP (CD:[1959..1962] two) (JJ:[1963..1974] nonspecific)
                        (NNS:[1975..1985] inhibitors))
                    (PP (IN:[1987..1989] of)
                      (NP
                        (ADJP
                          (NML (NN:[1990..2000] cytochrome)
                               (NN:[2001..2005] P450))
                          (HYPH:[2005..2006] -) (JJ:[2006..2015] dependent))
                        (NN:[2016..2028] arachidonate)
                         (NN:[2029..2039] metabolism))))))))
          (,:[2039..2040] ,)
          (SBAR-ADV (IN:[2041..2048] whereas)
            (S
              (NP-SBJ
                (NP
                  (NP (DT:[2049..2051] an) (NN:[2052..2061] inhibitor))
                  (PP (IN:[2062..2064] of)
                    (NP (NN:[2066..2077] epoxygenase))))
                (,:[2077..2078] ,)
                (NP (NN:[2079..2089] miconazole)))
              (,:[2089..2090] ,)
              (VP (VBD:[2091..2094] was) (RB:[2095..2098] not)
                (ADJP-PRD (JJ:[2099..2108] effective))))))))
    (.:[2108..2109] .)))

;sentence 15 Span:2110..2250
;Infusion of  20-hydroxyeicosatetraenoic acid (20-HETE) at a dose of 10(-10)
;mol/kg/min  decreased medullary Na+,K+-ATPase activity by 24.2%.
;[2123..2154]:substance:"20-hydroxyeicosatetraenoic acid"
;[2156..2163]:substance:"20-HETE"
;[2178..2185]:quantitative-value:"10(-10)"
;[2186..2196]:quantitative-units:"mol/kg/min"
;[2218..2221]...[2224..2231]:substance:"Na+"..."-ATPase"
;[2222..2231]:substance:"K+-ATPase"
;[2244..2249]:quantitative-value:"24.2%"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[2110..2118] Infusion))
      (PP (IN:[2119..2121] of)
        (NP
          (NP (JJ:[2123..2149] 20-hydroxyeicosatetraenoic)
              (NN:[2150..2154] acid))
          (NP (-LRB-:[2155..2156] -LRB-) (NN:[2156..2163] 20-HETE)
              (-RRB-:[2163..2164] -RRB-))))
      (PP (IN:[2165..2167] at)
        (NP
          (NP (DT:[2168..2169] a) (NN:[2170..2174] dose))
          (PP (IN:[2175..2177] of)
            (NP
              (NP (CD:[2178..2185] 10-LRB--10-RRB-) (NN:[2186..2189] mol))
              (PP (SYM:[2189..2190] /)
                (NP (NN:[2190..2192] kg)))
              (PP (SYM:[2192..2193] /)
                (NP (NN:[2193..2196] min))))))))
    (VP (VBD:[2198..2207] decreased)
      (NP (JJ:[2208..2217] medullary)
        (NML
          (NML
            (NML (NN:[2218..2220] Na) (SYM:[2220..2221] +))
            (,:[2221..2222] ,)
            (NML (NN:[2222..2223] K) (SYM:[2223..2224] +)))
          (HYPH:[2224..2225] -) (NN:[2225..2231] ATPase))
        (NN:[2232..2240] activity))
      (PP-EXT (IN:[2241..2243] by)
        (NP (CD:[2244..2248] 24.2) (NN:[2248..2249] %))))
    (.:[2249..2250] .)))

;sentence 16 Span:2251..2474
;Exogenous protein  phosphatases inhibitor, okadaic acid (OA, 10(-8) - 10(-7)
;mol/kg/min) caused  dose-dependent decrease in renal medullary Na+,K+-ATPase
;activity, maximally by  31.9%, but had no effect in the renal cortex.
;[2261..2282]:substance:"protein  phosphatases"
;[2283..2292]:substance:"inhibitor"
;[2294..2306]:substance:"okadaic acid"
;[2308..2310]:substance:"OA"
;[2312..2327]:quantitative-value:"10(-8) - 10(-7)"
;[2328..2338]:quantitative-units:"mol/kg/min"
;[2391..2394]...[2397..2404]:substance:"Na+"..."-ATPase"
;[2395..2404]:substance:"K+-ATPase"
;[2429..2434]:quantitative-value:"31.9%"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[2251..2260] Exogenous)
        (NML (NN:[2261..2268] protein) (NNS:[2270..2282] phosphatases))
        (NN:[2283..2292] inhibitor))
      (,:[2292..2293] ,)
      (NP
        (NP (JJ:[2294..2301] okadaic) (NN:[2302..2306] acid))
        (PRN (-LRB-:[2307..2308] -LRB-)
          (FRAG
            (NP (NN:[2308..2310] OA))
            (,:[2310..2311] ,)
            (NP
              (NP
                (QP (CD:[2312..2318] 10-LRB--8-RRB-) (HYPH:[2319..2320] -)
                    (CD:[2321..2327] 10-LRB--7-RRB-))
                (NN:[2328..2331] mol))
              (PP (SYM:[2331..2332] /)
                (NP (NN:[2332..2334] kg)))
              (PP (SYM:[2334..2335] /)
                (NP (NN:[2335..2338] min)))))
          (-RRB-:[2338..2339] -RRB-))))
    (VP
      (VP (VBD:[2340..2346] caused)
        (NP
          (ADJP (NN:[2348..2352] dose) (HYPH:[2352..2353] -)
                (JJ:[2353..2362] dependent))
          (NN:[2363..2371] decrease))
        (PP (IN:[2372..2374] in)
          (NP (JJ:[2375..2380] renal) (JJ:[2381..2390] medullary)
            (NML
              (NML
                (NML (NN:[2391..2393] Na) (SYM:[2393..2394] +))
                (,:[2394..2395] ,)
                (NML (NN:[2395..2396] K) (SYM:[2396..2397] +)))
              (HYPH:[2397..2398] -) (NN:[2398..2404] ATPase))
            (NN:[2405..2413] activity)))
        (,:[2413..2414] ,)
        (PP-EXT
          (ADVP (RB:[2415..2424] maximally))
          (IN:[2425..2427] by)
          (NP (CD:[2429..2433] 31.9) (NN:[2433..2434] %))))
      (,:[2434..2435] ,) (CC:[2436..2439] but)
      (VP (VBD:[2440..2443] had)
        (NP (DT:[2444..2446] no) (NN:[2447..2453] effect))
        (PP (IN:[2454..2456] in)
          (NP (DT:[2457..2460] the) (JJ:[2461..2466] renal)
              (NN:[2467..2473] cortex)))))
    (.:[2473..2474] .)))

;sentence 17 Span:2475..2545
;The effects of OA and db-cAMP in  the renal medulla were not additive.
;[2490..2492]:substance:"OA"
;[2497..2504]:substance:"db-cAMP"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2475..2478] The) (NNS:[2479..2486] effects))
      (PP (IN:[2487..2489] of)
        (NP (NN:[2490..2492] OA) (CC:[2493..2496] and) (NN:[2497..2504] db-cAMP)))
      (PP-LOC (IN:[2505..2507] in)
        (NP (DT:[2509..2512] the) (JJ:[2513..2518] renal)
            (NN:[2519..2526] medulla))))
    (VP (VBD:[2527..2531] were) (RB:[2532..2535] not)
      (ADJP-PRD (JJ:[2536..2544] additive)))
    (.:[2544..2545] .)))

;sentence 18 Span:2546..2721
;When OA administration (10(-7) mol/kg/min)  was followed by 20-HETE (10(-10)
;mol/kg/min), medullary Na+,K-ATPase activity  decreased by 48.6% and was
;similar as after db-cAMP.
;[2551..2553]:substance:"OA"
;[2570..2576]:quantitative-value:"10(-7)"
;[2577..2587]:quantitative-units:"mol/kg/min"
;[2606..2613]:substance:"20-HETE"
;[2615..2622]:quantitative-value:"10(-10)"
;[2623..2633]:quantitative-units:"mol/kg/min"
;[2646..2649]...[2651..2658]:substance:"Na+"..."-ATPase"
;[2650..2658]:substance:"K-ATPase"
;[2682..2687]:quantitative-value:"48.6%"
;[2713..2720]:substance:"db-cAMP"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-1 (WRB:[2546..2550] When))
      (S
        (NP-SBJ-2 (NN:[2551..2553] OA) (NN:[2554..2568] administration)
          (PRN (-LRB-:[2569..2570] -LRB-)
            (NP
              (NP (CD:[2570..2576] 10-LRB--7-RRB-) (NN:[2577..2580] mol))
              (PP (SYM:[2580..2581] /)
                (NP (NN:[2581..2583] kg)))
              (PP (SYM:[2583..2584] /)
                (NP (NN:[2584..2587] min))))
            (-RRB-:[2587..2588] -RRB-)))
        (VP (VBD:[2590..2593] was)
          (VP (VBN:[2594..2602] followed)
            (NP-2 (-NONE-:[2602..2602] *))
            (PP (IN:[2603..2605] by)
              (NP-LGS (NN:[2606..2613] 20-HETE)
                (PRN (-LRB-:[2614..2615] -LRB-)
                  (NP
                    (NP (CD:[2615..2622] 10-LRB--10-RRB-) (NN:[2623..2626] mol))
                    (PP (SYM:[2626..2627] /)
                      (NP (NN:[2627..2629] kg)))
                    (PP (SYM:[2629..2630] /)
                      (NP (NN:[2630..2633] min))))
                  (-RRB-:[2633..2634] -RRB-))))
            (ADVP-TMP-1 (-NONE-:[2634..2634] *T*))))))
    (,:[2634..2635] ,)
    (NP-SBJ (JJ:[2636..2645] medullary)
      (NML
        (NML
          (NML (NN:[2646..2648] Na) (SYM:[2648..2649] +))
          (,:[2649..2650] ,)
          (NML (NN:[2650..2651] K)))
        (HYPH:[2651..2652] -) (NN:[2652..2658] ATPase))
      (NN:[2659..2667] activity))
    (VP
      (VP (VBD:[2669..2678] decreased)
        (PP-EXT (IN:[2679..2681] by)
          (NP (CD:[2682..2686] 48.6) (NN:[2686..2687] %))))
      (CC:[2688..2691] and)
      (VP (VBD:[2692..2695] was)
        (ADJP-PRD (JJ:[2696..2703] similar)
          (PP (IN:[2704..2706] as)
            (PP-TMP (IN:[2707..2712] after)
              (NP (NN:[2713..2720] db-cAMP)))))))
    (.:[2720..2721] .)))

;sentence 19 Span:2722..2837
;We conclude, that cAMP-PKA  pathway activates Na+,K+-ATPase in the renal
;cortex and inhibits in the renal  medulla.
;[2740..2744]:substance:"cAMP"
;[2745..2748]:substance:"PKA"
;[2768..2771]...[2774..2781]:substance:"Na+"..."-ATPase"
;[2772..2781]:substance:"K+-ATPase"
(SENT
  (S
    (NP-SBJ (PRP:[2722..2724] We))
    (VP (VBP:[2725..2733] conclude) (,:[2733..2734] ,)
      (SBAR (IN:[2735..2739] that)
        (S
          (NP-SBJ
            (NML (NN:[2740..2744] cAMP) (HYPH:[2744..2745] -)
                 (NN:[2745..2748] PKA))
            (NN:[2750..2757] pathway))
          (VP
            (VP (VBZ:[2758..2767] activates)
              (NP
                (NML
                  (NML (NN:[2768..2770] Na) (SYM:[2770..2771] +))
                  (,:[2771..2772] ,)
                  (NML (NN:[2772..2773] K) (SYM:[2773..2774] +)))
                (HYPH:[2774..2775] -) (NN:[2775..2781] ATPase))
              (PP-LOC (IN:[2782..2784] in)
                (NP (DT:[2785..2788] the) (JJ:[2789..2794] renal)
                    (NN:[2795..2801] cortex))))
            (CC:[2802..2805] and)
            (VP (VBZ:[2806..2814] inhibits)
              (PP-LOC (IN:[2815..2817] in)
                (NP (DT:[2818..2821] the) (JJ:[2822..2827] renal)
                    (NN:[2829..2836] medulla))))))))
    (.:[2836..2837] .)))

;sentence 20 Span:2838..3008
;The inhibitory effect is partially mediated by cytochrome  P450-dependent
;arachidonate metabolites and possibly also by PKA-dependent  inhibition of
;protein phosphatases.
;[2885..2901]:cyp450:"cytochrome  P450"
;[2912..2936]:substance:"arachidonate metabolites"
;[2958..2961]:substance:"PKA"
;[2987..3007]:substance:"protein phosphatases"
(SENT
  (S
    (NP-SBJ-1 (DT:[2838..2841] The) (JJ:[2842..2852] inhibitory)
              (NN:[2853..2859] effect))
    (VP (VBZ:[2860..2862] is)
      (VP
        (ADVP (RB:[2863..2872] partially))
        (VBN:[2873..2881] mediated)
        (NP-1 (-NONE-:[2881..2881] *))
        (PP
          (PP (IN:[2882..2884] by)
            (NP-LGS
              (ADJP
                (NML (NN:[2885..2895] cytochrome) (NN:[2897..2901] P450))
                (HYPH:[2901..2902] -) (JJ:[2902..2911] dependent))
               (NN:[2912..2924] arachidonate) (NNS:[2925..2936] metabolites)))
          (CONJP (CC:[2937..2940] and) (RB:[2941..2949] possibly)
                 (RB:[2950..2954] also))
          (PP (IN:[2955..2957] by)
            (NP-LGS
              (NP
                (ADJP (NN:[2958..2961] PKA) (HYPH:[2961..2962] -)
                      (JJ:[2962..2971] dependent))
                (NN:[2973..2983] inhibition))
              (PP (IN:[2984..2986] of)
                (NP (NN:[2987..2994] protein) (NNS:[2995..3007] phosphatases))))))))
    (.:[3007..3008] .)))

;section 21 Span:3012..3057
;PMID: 12120897 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[3012..3016] PMID) (::[3016..3017] :) (CD:[3018..3026] 12120897)
        (NN:[3027..3028] -LSB-) (NNP:[3028..3034] PubMed) (::[3035..3036] -)
        (NN:[3037..3044] indexed) (IN:[3045..3048] for)
        (NNP:[3049..3057] MEDLINE-RSB-)))
